Corrigendum to: Global position paper on cardiovascular regenerative medicine (European Heart Journal (2017) 38:33 (2532-2546) DOI: 10.1093/eurheartj/ehx248);Global position paper on cardiovascular regenerative medicine

European Heart Journal

Volumn 38, Issue 33, 2017, Pages 2532-2546

  Fernández Avilés, Francisco ^a,b   Sanz Ruiz, Ricardo ^a,b   Climent, Andreu M ^a,b   Badimon, Lina ^b,c   Bolli, Roberto ^d   Charron, Dominique ^e   Fuster, Valentin ^b,f,g   Janssens, Stefan ^h   Kastrup, Jens ⁱ   Kim, Hyo Soo ^j,aw   Lüscher, Thomas F ^k,ax   Martin, John F ^l   Menasche, Philippe ^m   Simari, Robert D ⁿ   Stone, Gregg W ^o   Terzic, Andre ^p,q   Willerson, James T ^r   Wu, Joseph C ^s   Joseph, C Wu ^s   Weny, T ^p   Broughton, Kathleen ^t   DiFede, Darcy L ^u   Dimmeler, Stefanie ^v   Madonna, Rosalinda ^w   Penn, Marc S ^x   Sussman, Mark A ^t   Sluijter, Joost P G ^x,y,z   Woller, Kai C ^aa   Balkan, Wayne ^s   Chamuleau, Steven ^y   Fernández Santos, Maria Eugenia ^a,b   Goliasch, Georg ^ab,ac   Gyöngyösi, Mariann ^ab,ac   Hare, Joshua M ^u   Tompkins, Bryon A ^u   Winkler, Johannes ^ab   Bayés Genis, Antoni ^b,ad   Henry, Timothy D ^ae   Taylor, Doris A ^r   Lerman, Amir ^p   Pelacho, Beatriz ^ae   Prosper, Felipe ^af   Perin, Emerson C ^r   Pompilio, Giulio ^ag   Gersh, Bernard ^p   Bartunek, Jozef ^ah   Duckers, Eric ^ai   Ferdinandy, Péter ^aj,ak   Losordo, Douglas W ^al   Čanchez, Pedro L ^b,am   Sherman, Warren ^an   Wojakowski, Wojtek ^ao   Zeiher, Andreas ^ap   Roncalli, Jerome ^aq   Mathur, Anthony ^l   Crea, Filippo ^ar   D'Amario, Domenico ^ar   Povsic, Thomas J ^as,at   Traverse, Jay ^au   Yla Herttuala, Seppo ^av   more..

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^d University of Louisville School of Medicine   (United States)

^e SAINT LOUIS HOSPITAL   (France)

^f CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

^g MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF LEUVEN   (Belgium)

ⁱ Rigshospitalet   (Denmark)

^j Seoul National University Hospital   (South Korea)

^k UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^l UNIVERSITY COLLEGE LONDON   (United Kingdom)

^m HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

ⁿ UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^o CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

^p Department of Medicine   (United States)

^q MAYO GRADUATE SCHOOL   (United States)

^r TEXAS HEART INSTITUTE   (United States)

^s STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^t SAN DIEGO STATE UNIVERSITY   (United States)

^u UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^v GOETHE UNIVERSITY   (Germany)

^w UNIVERSITY OF CHIETI   (Italy)

^x NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^y UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^z INTERUNIVERSITY CARDIOLOGY INSTITUTE OF THE NETHERLANDS   (Netherlands)

^aa HANNOVER MEDICAL SCHOOL   (Germany)

^ab MEDICAL UNIVERSITY OF VIENNA   (Austria)

^ac HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^ad UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^ae CEDARS SINAI MEDICAL CENTER   (United States)

^af UNIVERSITY CLINIC OF NAVARRA   (Spain)

^ag UNIVERSITY OF MILAN   (Italy)

^ah OLV HOSPITAL   (Belgium)

^ai ERASMUS MEDICAL CENTER   (Netherlands)

^aj SEMMELWEIS UNIVERSITY   (Hungary)

^ak NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^al NORTHWESTERN UNIVERSITY   (United States)

^am Universidad de Salamanca   (Spain)

^an CELYAD   (Belgium)

^ao MEDICAL UNIVERSITY OF SILESIA   (Poland)

^ap UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^aq UNIVERSITÉ PAUL SABATIER   (France)

^ar CATHOLIC UNIVERSITY   (Italy)

^as DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^at MINNEAPOLIS HEART INSTITUTE FOUNDATION   (United States)

^au UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^av UNIVERSITY OF EASTERN FINLAND   (Finland)

^aw Seoul National University   (South Korea)

^ax UNIVERSITY OF ZURICH   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOMATERIAL;

ACUTE HEART INFARCTION; ANGINA PECTORIS; ANGIOGENESIS; BASIC RESEARCH; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CARDIAC STEM CELL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR TISSUE; CEREBROVASCULAR ACCIDENT; CLINICAL RESEARCH; EMBRYONIC STEM CELL; ENDOTHELIAL PROGENITOR CELL; HEART MUSCLE ISCHEMIA; HUMAN; INDUCED PLURIPOTENT STEM CELL; NONHUMAN; NOTE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; REGENERATIVE MEDICINE; STEM CELL TRANSPLANTATION; TISSUE ENGINEERING; TRANSLATIONAL RESEARCH; CONSENSUS; PERSONALIZED MEDICINE; PROCEDURES;

CARDIOVASCULAR DISEASES; CONSENSUS; HUMANS; PRECISION MEDICINE; REGENERATIVE MEDICINE;

EID: 85032470854     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehx599     Document Type: Erratum

References (155)

1. Bergmann O, Zdunek S, Felker A, Salehpour M, Alkass K, Bernard S, Sjostrom SL, Szewczykowska M, Jackowska T, Dos Remedios C, Malm T, Andrä M, Jashari R, Nyengaard JR, Possnert G, Jovinge S, Druid H, Frisén J. Dynamics of cell generation and turnover in the human heart. Cell 2015;161:1566-1575.
2. Sanz-Ruiz R, Bolli R, Gersh BJ, Janssens S, Menasché P, Perin EC, Taylor DA, Terzic A, Willerson F, Ferńandez-Avilés F. The TACTICS intitiative: Time for a global alliance on cardiovascular regenerative medicine. Eur Heart J 2016;37:2208-2211.
3. Aguirre A, Sancho-Martinez I, Izpisua Belmonte JC. Reprogramming toward heart regeneration: Stem cells and beyond. Cell Stem Cell 2013;12:275-284.
4. Beltrami AP, Urbanek K, Kajstura J, Yan SM, Finato N, Bussani R, Nadal-Ginard B, Silvestri F, Leri A, Beltrami CA, Anversa P. Evidence that human cardiac myocytes divide after myocardial infarction. N Engl J Med 2001;344:1750-1757.
5. Kikuchi K, Poss KD. Cardiac regenerative capacity and mechanisms. Annu Rev Cell Dev Biol 2012;28:719-741.
6. Porrello ER, Mahmoud AI, Simpson E, Hill JA, Richardson JA, Olson EN, Sadek HA. Transient regenerative potential of the neonatal mouse heart. Science 2011;331:1078-1080.
7. Beltrami AP, Barlucchi L, Torella D, Baker M, Limana F, Chimenti S, Kasahara H, Rota M, Musso E, Urbanek K, Leri A, Kajstura J, Nadal-Ginard B, Anversa P. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 2003;114:763-776.
8. Porrello ER, Olson EN. A neonatal blueprint for cardiac regeneration. Stem Cell Res 2014;13:556-570.
9. Jopling C, Boue S, Izpisua Belmonte JC. Dedifferentiation, transdifferentiation and reprogramming: Three routes to regeneration. Nat Rev Mol Cell Biol 2011;12:79-89.
10. Kovacic JC, Fuster V. Cell therapy for patients with acute myocardial infarction: ACCRUEd evidence to date. Circ Res 2015;116:1287-1290.
11. Sadahiro T, Yamanaka S, Ieda M. Direct cardiac reprogramming. Circ Res 2015;116:1378-1391.
12. Zhou B, Ma Q, Rajagopal S, Wu SM, Domian I, Rivera-Feliciano J, Jiang D, von Gise A, Ikeda S, Chien KR, Pu WT. Epicardial progenitors contribute to the cardiomyocyte lineage in the developing heart. Nature 2008;454:109-113.
13. Ruiz-Villalba A, Simon AM, Pogontke C, Castillo MI, Abizanda G, Pelacho B, Sanchez-Dominguez R, Segovia JC, Prosper F, Pérez-Pomares JM. Interacting resident epicardium-derived fibroblasts and recruited bone marrow cells form myocardial infarction scar. J Am Coll Cardiol 2015;65:2057-2066.
14. Botham CM, Bennett WL, Cooke JP. Clinical trials of adult stem cell therapy for peripheral artery disease. Methodist Debakey Cardiovasc J 2013;9:201-205.
15. Hagensen MK, Vanhoutte PM, Bentzon JF. Arterial endothelial cells: Still the craftsmen of regenerated endothelium. Cardiovasc Res 2012;95:281-289.
16. Hirase T, Node K. Endothelial dysfunction as a cellular mechanism for vascular failure. Am J Physiol Heart Circ Physiol 2012;302:H499-H505.
17. Hong X, Le Bras A, Margariti A, Xu Q. Reprogramming towards endothelial cells for vascular regeneration. Genes Dis 2016;3:186-197.
18. Mocharla P, Briand S, Giannotti G, Dörries C, Jakob P, Paneni F, Lüscher T, Landmesser U. AngiomiR-126 expression and secretion from circulating CD34 and CD14 PBMCs: Role for proangiogenic effects and alterations in type 2 diabetics. Blood 2013;121:226-236.
19. Jakob P, Doerries C, Briand S, Mocharla P, Krankel N, Besler C, Mueller M, Manes C, Templin C, Baltes C, Rudin M, Adams H, Wolfrum M, Noll G, Ruschitzka F, Luscher TF, Landmesser U. Loss of AngiomiR-126 and 130a in angiogenic early outgrowth cells from patients with chronic heart failure: Role for impaired in vivo neovascularization and cardiac repair capacity. Circulation 2012;126:2962-2975.
20. Giannotti G, Doerries C, Mocharla PS, Mueller MF, Bahlmann FH, Horv-ath T, Jiang H, Sorrentino SA, Steenken N, Manes C, Marzilli M, Rudolph KL, Lüscher TF, Drexler H, Landmesser U. Impaired endothelial repair capacity of early endothelial progenitor cells in prehypertension: Relation to endothelial dysfunction. Hypertension 2010;55:1389-1397.
21. Paneni F, Costantino S, Kränkel N, Cosentino F, Lüscher TF. Reprogramming ageing and longevity genes restores paracrine angiogenic properties of early outgrowth cells. Eur Heart J 2016;37:1733-1737.
22. Ott HC, Matthiesen TS, Goh S, Black LD, Kren SM, Netoff TI, Taylor DA. Perfusion-decellularized matrix: Using nature's platform to engineer a bioartificial heart. Nat Med 2008;14:213-221.
23. Sanchez PL, Fernandez-Santos ME, Costanza S, Climent AM, Moscoso I, Gonzalez-Nicolas MA, Sanz-Ruiz R, Rodriguez H, Kren SM, Garrido G, Escalante JL, Bermejo J, Elizaga J, Menarguez J, Yotti R, Pérez del Villar C, Espinosa MA, Guillem MS, Willerson JT, Bernad A, Matesanz R, Taylor DA, Fernandez-Avilés F. Acellular human heart matrix: A critical step toward whole heart grafts. Biomaterials 2015;61:279-289.
24. Guyette JP, Charest JM, Mills RW, Jank BJ, Moser PT, Gilpin SE, Gershlak JR, Okamoto T, Gonzalez G, Milan DJ, Gaudette GR, Ott HC. Bioengineering human myocardium on native extracellular matrix. Circ Res 2016;118:56-72.
25. Garreta E, de Oñate L, Ferńandez-Santos ME, Oria R, Tarantino C, Climent AM, Marco A, Samitier M, Martínez E, Valls-Margarit M, Matesanz R, Taylor DA, Ferńandez-Avilés F, Izpisua Belmonte JC, Montserrat N. Myocardial commitment from human pluripotent stem cells: Rapid production of human heart grafts. Biomaterials 2016;98:64-78.
26. Chong JJH, Yang X, Don CW, Minami E, Liu Y-W, Weyers JJ, Mahoney WM, Van Biber B, Cook SM, Palpant NJ, Gantz JA, Fugate JA, Muskheli V, Gough GM, Vogel KW, Astley CA, Hotchkiss CE, Baldessari A, Pabon L, Reinecke H, Gill EA, Nelson V, Kiem H-P, Laflamme M, Murry CE. Human embryonic-stem-cellderived cardiomyocytes regenerate non-human primate hearts. Nature 2014;510:273-277.
27. Blin G, Nury D, Stefanovic S, Neri T, Guillevic O, Brinon B, Bellamy V, Rücker-Martin C, Barbry P, Bel A, Bruneval P, Cowan C, Pouly J, Mitalipov S, Gouadon E, Binder P, Hagège A, Desnos M, Renaud JF, Menasché P, Pucéat M. A purified population of multipotent cardiovascular progenitors derived from primate pluripotent stem cells engrafts in postmyocardial infarcted nonhuman primates. J Clin Invest 2010;120:1125-1139.
28. Menasché P, Vanneaux V, Hagège A, Bel A, Cholley B, Cacciapuoti I, Parouchev A, Benhamouda N, Tachdjian G, Tosca L, Trouvin J, Fabreguettes J, Bellamy V, Guillemain R, Suberbielle Boissel C, Tartour E, Desnos M, Larghero J. Human embryonic stem cell-derived cardiac progenitors for severe heart failure treatment: First clinical case report. Eur Heart J 2015;36:2011-2017.
29. Madonna R, Van Laake L, Davidson S, Engel F, Hausenloy D, Lecour S, Leor J, Perrino C, Schulz R, Ytrehus K, Landmesser U, Mummery C, Janssens S, Willerson J, Eschenhagen T, Ferdinandy P, Sluijter J. Position Paper of the European Society of Cardiology Working Group Cellular Biology of the Heart: Cell-based therapies for myocardial repair and regeneration in ischemic heart disease and heart failure. Eur Heart J 2016;37:1789-1798.
30. Broughton KM, Sussman MA. Empowering adult stem cells for myocardial regeneration V2.0. Circ Res 2016;118:867-880.
31. Zafiriou MP, Noack C, Unsöld B, Didie M, Pavlova E, Fischer HJ, Reichardt HM, Bergmann MW, El-Armouche A, Zimmermann WH, Zelarayan LC. Erythropoietin responsive cardiomyogenic cells contribute to heart repair post myocardial infarction. Stem Cells 2014;32:2480-2491.
32. Barile L, Lionetti V, Cervio E, Matteucci M, Gherghiceanu M, Popescu LM, Torre T, Siclari F, Moccetti T, Vassalli G. Extracellular vesicles from human cardiac progenitor cells inhibit cardiomyocyte apoptosis and improve cardiac function after myocardial infarction. Cardiovasc Res 2014;103:1-24.
33. Emanueli C, Shearn AIU, Angelini GD, Sahoo S. Exosomes and exosomal miRNAs in cardiovascular protection and repair. Vascul Pharmacol 2015;71:24-30.
34. De Jong R, Van Hout GPJ, Houtgraaf JH, Kazemi K, Wallrapp C, Lewis A, Pasterkamp G, Hoefer IE, Duckers HJ. Intracoronary infusion of encapsulated glucagon-like peptide-1-eluting mesenchymal stem cells preserves left ventricular function in a porcine model of acute myocardial infarction. Circ Cardiovasc Interv 2014;7:673-683.
35. Seif-Naraghi SB, Singelyn JM, Salvatore MA, Osborn KG, Wang JJ, Sampat U, Kwan OL, Strachan GM, Wong J, Schup-Magoffin PJ, Braden RL, Bartels K, DeQuach JA, Preul M, Kinsey AM, DeMaria AN, Dib N, Christman KL. Safety and efficacy of an injectable extracellular matrix hydrogel for treating myocardial infarction. Sci Transl Med 2013;5:173ra25.
36. Madonna R, Taylor DA, Geng YJ, De Caterina R, Shelat H, Perin EC, Willerson JT. Transplantation of mesenchymal cells rejuvenated by the overexpression of telomerase and myocardin promotes revascularization and tissue repair in a murine model of hindlimb ischemia. Circ Res 2013;113:902-914.
37. Chung ES, Miller L, Patel AN, Anderson RD, Mendelsohn FO, Traverse J, Silver KH, Shin J, Ewald G, Farr MJ, Anwaruddin S, Plat F, Fisher SJ, AuWerter AT, Pastore JM, Aras R, Penn MS. Changes in ventricular remodelling and clinical status during the year following a single administration of stromal cell-derived factor-1 non-viral gene therapy in chronic ischaemic heart failure patients: The STOP-HF randomized Phase II trial. Eur Heart J 2015;36:2228-2238.
38. Bär C, Bernardes de Jesus B, Serrano R, Tejera A, Ayuso E, Jimenez V, Formentini I, Bobadilla M, Mizrahi J, de Martino A, Gomez G, Pisano D, Mulero F, Wollert KC, Bosch F, Blasco MA. Telomerase expression confers cardioprotection in the adult mouse heart after acute myocardial infarction. Nat Commun 2014;5:5863.
39. Vunjak Novakovic G, Eschenhagen T, Mummery C, Novakovic GV, Eschenhagen T, Mummery C. Myocardial tissue engineering: In vitro models. Cold Spring Harb Perspect Med 2014;4:1-16.
40. Breckwoldt K, Weinberger F, Eschenhagen T. Heart regeneration. Biochim Biophys Acta 2016;1863:1749-1759.
41. Van Der Spoel TIG, Jansen Of Lorkeers SJ, Agostoni P, Van Belle E, Gyngysi M, Sluijter JPG, Cramer MJ, Doevendans PA, Chamuleau SAJ, Gyöngyösi M, Sluijter JPG, Cramer MJ, Doevendans PA, Chamuleau SAJ. Human relevance of preclinical studies in stem cell therapy: Systematic review and meta-analysis of large animal models of ischaemic heart disease. Cardiovasc Res 2011;91:649-658.
42. Jansen Of Lorkeers SJ, Eding JEC, Vesterinen HM, van der Spoel TIG, Sena ES, Duckers HJ, Doevendans PA, Macleod MR, Chamuleau SAJ. Similar effect of autologous and allogeneic cell therapy for ischemic heart disease: Systematic review and meta-analysis of large animal studies. Circ Res 2015;116:80-86.
43. Zwetsloot PP, Végh AM, Jansen Of Lorkeers SJ, van Hout GP, Currie GL, Sena ES, Gremmels H, Buikema JW, Goumans MJ, Macleod MR, Doevendans PA, Chamuleau SA, Sluijter JP. Cardiac stem cell treatment in myocardial infarction: A systematic review and meta-analysis of preclinical studies. Circ Res 2016;118:1223-1232.
44. Soares MBP, Lima RS, Rocha LL, Takyia CM, Pontes-de-Carvalho L, de Carvalho AC, Ribeiro-dos-Santos R. Transplanted bone marrow cells repair heart tissue and reduce myocarditis in chronic chagasic mice. Am J Pathol 2004;164:441-447.
45. Goldenberg RCS, Jelicks LA, Fortes FSA, Weiss LM, Rocha LL, Zhao D, de Carvalho AC, Spray DC, Tanowitz HB. Bone marrow cell therapy ameliorates and reverses chagasic cardiomyopathy in a mouse model. J Infect Dis 2008;197:544-547.
46. Strauer BE, Brehm M, Zeus T, Köstering M, Hernandez A, Sorg RV, Kögler G, Wernet P. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation 2002;106:1913-1918.
47. Peruzzi M, De Falco E, Abbate A, Biondi-Zoccai G, Chimenti I, Lotrionte M, Benedetto U, Delewi R, Marullo AGM, Frati G, Peruzzi M, De Falco E, Abbate A, Biondi-Zoccai G, Chimenti I, Lotrionte M, Benedetto U, Delewi R, Marullo AGM, Frati G. State of the art on the evidence base in cardiac regenerative therapy: Overview of 41 systematic reviews. Biomed Res Int 2015;2015:613782.
48. Cao F, Sun D, Li C, Narsinh K, Zhao L, Li X, Feng X, Zhang J, Duan Y, Wang J, Liu D, Wang H. Long-term myocardial functional improvement after autologous bone marrow mononuclear cells transplantation in patients with ST-segment elevation myocardial infarction: 4 years follow-up. Eur Heart J 2009;30:1986-1994.
49. Choudry F, Hamshere S, Saunders N, Veerapen J, Bavnbek K, Knight C, Pellerin D, Locca D, Westwood M, Rakhit R, Crake T, Kastrup J, Parmar M, Agrawal S, Jones D, Martin J, Mathur A. A randomized double-blind control study of early intra-coronary autologous bone marrow cell infusion in acute myocardial infarction: The REGENERATE-AMI clinical trial. Eur Heart J 2016;37:256-263.
50. Hirsch A, Nijveldt R, van der Vleuten PA, Tio RA, van der Giessen WJ, Marques KMJ, Doevendans PA, Waltenberger J, Ten Berg JM, Aengevaeren WRM, Biemond BJ, Tijssen JGP, van Rossum AC, Piek JJ, Zijlstra F. Intracoronary infusion of autologous mononuclear bone marrow cells in patients with acute myocardial infarction treated with primary PCI: Pilot study of the multicenter HEBE trial. Catheter Cardiovasc Interv 2008;71:273-281.
51. Huikuri HV, Kervinen K, Niemelä M, Ylitalo K, Säily M, Koistinen P, Savolainen ER, Ukkonen H, Pietilä M, Airaksinen JKE, Knuuti J, Mäkikallio TH. Effects of intracoronary injection of mononuclear bone marrow cells on left ventricular function, arrhythmia risk profile, and restenosis after thrombolytic therapy of acute myocardial infarction. Eur Heart J 2008;29:2723-2732.
52. Janssens S, Dubois C, Bogaert J, Theunissen K, Deroose C, Desmet W, Kalantzi M, Herbots L, Sinnaeve P, Dens J, Maertens J, Rademakers F, Dymarkowski S, Gheysens O, Van Cleemput J, Bormans G, Nuyts J, Belmans A, Mortelmans L, Boogaerts M, Van De Werf F. Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: Doubleblind, randomised controlled trial. Lancet 2006;367:113-121.
53. Lunde K, Solheim S, Aakhus S, Arnesen H, Abdelnoor M, Egeland T, Endresen K, Ilebekk A, Mangschau A, Fjeld JG, Smith HJ, Taraldsrud E, Grøgaard HK, Bjørnerheim R, Brekke M, Müller C, Hopp E, Ragnarsson A, Brinchmann JE, Forfang K. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N Engl J Med 2006;355:1199-1209.
54. Meluzin J, Mayer J, Groch L, Janousek S, Hornacek I, Hlinomaz O, Kala P, Panovsky R, Prasek J, Kaminek M, Stanicek J, Klabusay M, Koristek Z, Navratil M, Dusek L, Vinklarkova J. Autologous transplantation of mononuclear bone marrow cells in patients with acute myocardial infarction: The effect of the dose of transplanted cells on myocardial function. Am Heart J 2006;152:975.e9-915.
55. Plewka M, Krzeminska-Pakula M, Lipiec P. Effect of intracoronary injection of mononuclear bone marrow stem cells on left ventricular function in patients with acute myocardial infarction. Am J Cardiol 2009;104:1336-1342.
56. Roncalli J, Mouquet F, Piot C, Trochu JN, Le Corvoisier P, Neuder Y, Le Tourneau T, Agostini D, Gaxotte V, Sportouch C, Galinier M, Crochet D, Teiger E, Richard MJ, Polge AS, Beregi JP, Manrique A, Carrie D, Susen S, Klein B, Parini A, Lamirault G, Croisille P, Rouard H, Bourin P, Nguyen JM, Delasalle B, Vanzetto G, Van Belle E, Lemarchand P. Intracoronary autologous mononucleated bone marrow cell infusion for acute myocardial infarction: Results of the randomized multicenter BONAMI trial. Eur Heart J 2011;32:1748-1757.
57. San Roman JA, Sanchez PL, Villa A, Sanz-Ruiz R, Fernandez-Santos ME, Gimeno F, Ramos B, Arnold R, Serrador A, Gutiérrez H, Martin-Herrero F, Rollan MJ, Fernandez-Vazquez F, Lopez-Messa J, Ancillo P, Pérez-Ojeda G, Ferńandez-Avilés F. Comparison of different bone marrow-derived stem cell approaches in reperfused STEMI: A multicenter, prospective, randomized, open-labeled TECAM trial. J Am Coll Cardiol 2015;65:2372-2382.
58. Schächinger V, Erbs S, Elsässer A, Haberbosch W, Hambrecht R, Hölschermann H, Yu J, Corti R, Mathey DG, Hamm CW, Süselbeck T, Assmus B, Tonn T, Dimmeler S, Zeiher AM. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 2006;355:1210-1221.
59. Sürder D, Manka R, Lo Cicero V, Moccetti T, Rufibach K, Soncin S, Turchetto L, Radrizzani M, Astori G, Schwitter J, Erne P, Zuber M, Auf der Maur C, Jamshidi P, Gaemperli O, Windecker S, Moschovitis A, Wahl A, Bühler I, Wyss C, Kozerke S, Landmesser U, Lüscher TF, Corti R. Intracoronary injection of bone marrowderived mononuclear cells early or late after acute myocardial infarction: Effects on global left ventricular function. Circulation 2013;127:1968-1979.
60. Traverse JH, Henry TD, Pepine CJ, Willerson JT, Zhao DX, Ellis SG, Forder JR, Anderson RD, Hatzopoulos AK, Penn MS, Perin EC, Chambers J, Baran KW, Raveendran G, Lambert C, Lerman A, Simon DI, Vaughan DE, Lai D, Gee AP, Taylor DA, Cogle CR, Thomas JD, Olson RE, Bowman S, Francescon J, Geither C, Handberg E, Kappenman C, Westbrook L, Piller LB, Simpson LM, Baraniuk S, Loghin C, Aguilar D, Richman S, Zierold C, Spoon DB, Bettencourt J, Sayre SL, Vojvodic RW, Skarlatos SI, Gordon DJ, Ebert RF, Kwak M, Moyé LA, Simari RD. Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: The TIME randomized trial. JAMA 2012;308:2380-2389.
61. Wöhrle J, Merkle N, Mailänder V, Nusser T, Schauwecker P, von Scheidt F, Schwarz K, Bommer M, Wiesneth M, Schrezenmeier H, Hombach V. Results of intracoronary stem cell therapy after acute myocardial infarction. Am J Cardiol 2010;105:804-812.
62. Wollert KC, Meyer GP, Lotz J, Ringes-Lichtenberg S, Lippolt P, Breidenbach C, Fichtner S, Korte T, Hornig B, Messinger D, Arseniev L, Hertenstein B, Ganser A, Drexler H. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: The BOOST randomised controlled clinical trial. Lancet 2004;364:141-148.
63. Sürder D, Manka R, Moccetti T, Lo Cicero V, Emmert MY, Klersy C, Soncin S, Turchetto L, Radrizzani M, Zuber M, Windecker S, Moschovitis A, Bühler I, Kozerke S, Erne P, Lüscher TF, Corti R. The effect of bone marrow derived mononuclear cell treatment, early or late after acute myocardial infarction: Twelve months CMR and long-term clinical results. Circ Res 2016;119:481-490.
64. Lee JW, Lee SH, Youn YJ, Ahn MS, Kim JY, Yoo BS, Yoon J, Kwon W, Hong IS, Lee K, Kwan J, Park KS, Choi D, Jang YS, Hong MK. A randomized, open-label, multicenter trial for the safety and efficacy of adult mesenchymal stem cells after acute myocardial infarction. J Korean Med Sci 2014;29:23-31.
65. Assmus B, Schächinger V, Teupe C, Britten M, Lehmann R, Döbert N, Grünwald F, Aicher A, Urbich C, Martin H, Hoelzer D, Dimmeler S, Zeiher AM. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI). Circulation 2002;106:3009-3017.
66. Bartunek J, Vanderheyden M, Vandekerckhove B, Mansour S, De Bruyne B, De Bondt P, Van Haute I, Lootens N, Heyndrickx G, Wijns W. Intracoronary injection of CD133-positive enriched bone marrow progenitor cells promotes cardiac recovery after recent myocardial infarction: Feasibility and safety. Circulation 2005;112:178-183.
67. Colombo A, Castellani M, Piccaluga E, Pusineri E, Palatresi S, Longari V, Canzi C, Sacchi E, Rossi E, Rech R, Gerundini P, Viecca M, Deliliers GL, Rebulla P, Soligo D, Giordano R. Myocardial blood flow and infarct size after CD133 cell injection in large myocardial infarction with good recanalization and poor reperfusion: Results from a randomized controlled trial. J Cardiovasc Med (Hagerstown) 2011;12:239-248.
68. Quyyumi AA, Waller EK, Murrow J, Esteves F, Galt J, Oshinski J, Lerakis S, Sher S, Vaughan D, Perin E, Willerson J, Kereiakes D, Gersh BJ, Gregory D, Werner A, Moss T, Chan WS, Preti R, Pecora AL. CD34( ) cell infusion after ST elevation myocardial infarction is associated with improved perfusion and is dose dependent. Am Heart J 2011;161:98-105.
69. Tendera M, Wojakowski W, Ruzyłło W, Chojnowska L, Kepka C, Tracz W, Musiałek P, Piwowarska W, Nessler J, Buszman P, Grajek S, Breborowicz P, Majka M, Ratajczak MZ. Intracoronary infusion of bone marrow-derived selected CD34 CXCR4 cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction: Results of randomized, multicentre Myocardial Regeneration by Intracor. Eur Heart J 2009;30:1313-1321.
70. Houtgraaf JH, den Dekker WK, van Dalen BM, Springeling T, de Jong R, van Geuns RJ, Geleijnse ML, Fernandez-Aviles F, Zijlsta F, Serruys PW, Duckers HJ. First experience in humans using adipose tissue-derived regenerative cells in the treatment of patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol 2012;59:539-540.
71. Makkar RR, Smith RR, Cheng K, Malliaras K, Thomson LEJ, Berman D, Czer LSC, Marban L, Mendizabal A, Johnston PV, Russell SD, Schuleri KH, Lardo AC, Gerstenblith G, Marban E. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): A prospective, randomised phase 1 trial. Lancet 2012;379:895-904.
72. Hibbert B, Hayley B, Beanlands RS, Le May M, Davies R, So D, Marquis J-F, Labinaz M, Froeschl M, O'brien ER, Burwash IG, Wells G. A, Pourdjabbar A, Simard T, Atkins H, Glover C. Granulocyte colony-stimulating factor therapy for stem cell mobilization following anterior wall myocardial infarction: The CAPITAL STEM MI randomized trial. CMAJ 2014;186:427-434.
73. Ince H, Petzsch M, Kleine HD, Schmidt H, Rehders T, Körber T, Schümichen C, Freund M, Nienaber CA. Preservation from left ventricular remodeling by front-integrated revascularization and stem cell liberation in evolving acute myocardial infarction by use of granulocyte-colony-stimulating factor (FIRSTLINE-AMI). Circulation 2005;112:3097-3106.
74. Kang HJ, Lee HY, Na SH, Chang SA, Park KW, Kim HKHS, Kim SY, Chang HJ, Lee W, Kang WJ, Koo BK, Kim YJ, Lee DS, Sohn DW, Han KS, Oh BH, Park YB, Kim KH. Differential effect of intracoronary infusion of mobilized peripheral blood stem cells by granulocyte colony-stimulating factor on left ventricular function and remodeling in patients with acute myocardial infarction versus old myocardial infarction. Circulation 2006;114:145-151.
75. Lipinski MJ, Biondi-Zoccai GGL, Abbate A, Khianey R, Sheiban I, Bartunek J, Vanderheyden M, Kim HS, Kang HJ, Strauer BE, Vetrovec GW. Impact of intracoronary cell therapy on left ventricular function in the setting of acute myocardial infarction. A collaborative systematic review and meta-analysis of controlled clinical trials. J Am Coll Cardiol 2007;50:1761-1767.
76. Ripa RS, Jorgensen E, Wang Y, Thune JJ, Nilsson JC, Sondergaard L, Johnsen HE, Kober L, Grande PKJ. Stem cell mobilization induced by subcutaneous granulocyte-colony stimulating factor to improve cardiac regeneration after acute ST-elevation myocardial infarction: Result of the double-blind, randomized, placebo-controlled stem cells in myocardial infarc. Circulation 2006;113:1983-1992.
77. Zohlnhöfer D, Ott I, Mehilli J, Schömig K, Michalk F, Ibrahim T, Meisetschläger G, von Wedel J, Bollwein H, Seyfarth M, Dirschinger J, Schmitt C, Schwaiger M, Kastrati A, Schömig A. Stem cell mobilization by granulocyte colony-stimulating factor in patients with acute myocardial infarction: A randomized controlled trial. JAMA 2006;295:1003-1010.
78. Dib N, Dinsmore J, Lababidi Z, White B, Moravec S, Campbell A, Rosenbaum A, Seyedmadani K, Jaber WA, Rizenhour CS, Diethrich E. One-year follow-up of feasibility and safety of the first U.S., randomized, controlled study using 3-dimensional guided Catheter-Based Delivery of Autologous Skeletal Myoblasts for Ischemic Cardiomyopathy (CAuSMIC Study). JACC Cardiovasc Interv 2009;2:9-16.
79. Duckers HJ, Houtgraaf J, Hehrlein C, Schofer J, Waltenberger J, Gershlick A, Bartunek J, Nienaber C, Macaya C, Peters N, Smits P, Siminiak T, Van Mieghem W, Legrand V, Serruys PW. Final results of a phase IIa, randomised, open-label trial to evaluate the percutaneous intramyocardial transplantation of autologous skeletal myoblasts in congestive heart failure patients: The SEISMIC trial. Euro Intervention 2011;6:805-812.
80. Menasché P, Alfieri O, Janssens S, McKenna W, Reichenspurner H, Trinquart L, Vilquin JT, Marolleau JP, Seymour B, Larghero J, Lake S, Chatellier G, Solomon S, Desnos M, Hagège AA. The myoblast autologous grafting in ischemic cardiomyopathy (MAGIC) trial: First randomized placebo-controlled study of myoblast transplantation. Circulation 2008;117:1189-1200.
81. Povsic TJ, O'connor CM, Henry T, Taussig A, Kereiakes DJ, Fortuin FD, Niederman A, Schatz R, Spencer R, Owens D, Banks M, Joseph D, Roberts R, Alexander JH, Sherman W. A double-blind, randomized, controlled, multicenter study to assess the safety and cardiovascular effects of skeletal myoblast implantation by catheter delivery in patients with chronic heart failure after myocardial infarction. Am Heart J 2011;162:654-662.e1.
82. Hendrikx M, Hensen K, Clijsters C, Jongen H, Koninckx R, Bijnens E, Ingels M, Jacobs A, Geukens R, Dendale P, Vijgen J, Dilling D, Steels P, Mees U, Rummens JL. Recovery of regional but not global contractile function by the direct intramyocardial autologous bone marrow transplantation: Results from a randomized controlled clinical trial. Circulation 2006;114:101-107.
83. Hu S, Liu S, Zheng Z, Yuan X, Li L, Lu M, Shen R, Duan F, Zhang X, Li J, Liu X, Song Y, Wang W, Zhao S, He Z, Zhang H, Yang K, Feng W, Wang X. Isolated coronary artery bypass graft combined with bone marrow mononuclear cells delivered through a graft vessel for patients with previous myocardial infarction and chronic heart failure: A single-center, randomized, double-blind, placebocontrolled Cl. J Am Coll Cardiol 2011;57:2409-2415.
84. Mozid A, Yeo C, Arnous S, Ako E, Saunders N, Locca D, Brookman P, Archbold RA, Rothman M, Mills P, Agrawal S, Martin J, Mathur A. Safety and feasibility of intramyocardial versus intracoronary delivery of autologous cell therapy in advanced heart failure: The REGENERATE-IHD pilot study. Regen Med 2014;9:269-278.
85. Yao K, Huang R, Qian J, Cui J, Ge L, Li Y, Zhang F, Shi H, Huang D, Zhang S, Sun A, Zou Y, Ge J. Administration of intracoronary bone marrow mononuclear cells on chronic myocardial infarction improves diastolic function. Heart 2008;94:1147-1153.
86. Chen S, Liu Z, Tian N, Zhang J, Yei F, Duan B, Zhu Z, Lin S, Kwan TW. Intracoronary transplantation of autologous bone marrow mesenchymal stem cells for ischemic cardiomyopathy due to isolated chronic occluded left anterior descending artery. J Invasive Cardiol 2006;18:552-556.
87. Heldman AW, DiFede DL, Fishman JE, Zambrano JP, Trachtenberg BH, Karantalis V, Mushtaq M, Williams AR, Suncion VY, McNiece IK, Ghersin E, Soto V, Lopera G, Miki R, Willens H, Hendel R, Mitrani R, Pattany P, Feigenbaum G, Oskouei B, Byrnes J, Lowery MH, Sierra J, Pujol MV, Delgado C, Gonzalez PJ, Rodriguez JE, Bagno LL, Rouy D, Altman P, Foo CW, da Silva J, Anderson E, Schwarz R, Mendizabal A, Hare JM. Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: The TAC-HFT randomized trial. JAMA 2014;311:62-73.
88. Mathiasen AB, Qayyum AA, Jørgensen E, Helqvist S, Fischer-Nielsen A, Kofoed KF, Haack-Sørensen M, Ekblond A, Kastrup J. Bone marrow-derived mesenchymal stromal cell treatment in patients with severe ischaemic heart failure: A randomized placebo-controlled trial (MSC-HF trial). Eur Heart J 2015;36:1744-1753.
89. Assmus B, Honold J, Schächinger V, Britten MB, Fischer-Rasokat U, Lehmann R, Teupe C, Pistorius K, Martin H, Abolmaali ND, Tonn T, Dimmeler S, Zeiher AM. Transcoronary transplantation of progenitor cells after myocardial infarction. N Engl J Med 2006;355:1222-1232.
90. Honold J, Fischer-Rasokat U, Lehmann R, Leistner DM, Seeger FH, Schachinger V, Martin H, Dimmeler S, Zeiher AM, Assmus B. G-CSF stimulation and coronary reinfusion of mobilized circulating mononuclear proangiogenic cells in patients with chronic ischemic heart disease: Five-year results of the TOPCARE-G-CSF trial. Cell Transplant 2012;21:2325-2337.
91. Patel AN, Geffner L, Vina RF, Saslavsky J, Urschel HC, Kormos R, Benetti F. Surgical treatment for congestive heart failure with autologous adult stem cell transplantation: A prospective randomized study. J Thorac Cardiovasc Surg 2005;130:1631-1638.
92. Nasseri BA, Ebell W, Dandel M, Kukucka M, Gebker R, Doltra A, Knosalla C, Choi YH, Hetzer R, Stamm C. Autologous CD133 bone marrow cells and bypass grafting for regeneration of ischaemic myocardium: The Cardio133 trial. Eur Heart J 2014;35:1263-1274.
93. Perin EC, Silva GV, Zheng Y, Gahremanpour A, Canales J, Patel D, Fernandes MR, Keller LH, Quan X, Coulter SA, Moore WH, Herlihy JP, Willerson JT. Randomized, double-blind pilot study of transendocardial injection of autologous aldehyde dehydrogenase-bright stem cells in patients with ischemic heart failure. Am Heart J 2012;163:415-421.
94. Patel AN, Henry TD, Quyyumi AA, Schaer GL, Anderson RD, Toma C, East C, Remmers AE, Goodrich J. Ixmyelocel-T for patients with ischaemic heart failure: A prospective randomised double-blind trial. Lancet 2016;6736:1-10.
95. Bartunek J, Behfar A, Dolatabadi D, Vanderheyden M, Ostojic M, Dens J, El Nakadi B, Banovic M, Beleslin B, Vrolix M, Legrand V, Vrints C, Vanoverschelde JL, Crespo-Diaz R, Homsy C, Tendera M, Waldman S, Wijns W, Terzic A. Cardiopoietic stem cell therapy in heart failure: The C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineagespecified biologics. J Am Coll Cardiol 2013;61:2329-2338.
96. Assmus B, Walter DH, Seeger FH, Leistner DM, Lutz A, Dimmeler S, Steiner J, Ziegler I, Lutz A, Khaled W, Klotsche J, Tonn T, Dimmeler S, Zeiher AM. Effect of shock wave-facilitated intracoronary cell therapy on LVEF in patients with chronic heart failure: The CELLWAVE randomized clinical trial. JAMA 2013;309:1622-1631.
97. Bolli R, Chugh AR, D'amario D, Loughran JH, Stoddard MF, Ikram S, Beache GM, Wagner SG, Leri A, Hosoda T, Sanada F, Elmore JB, Goichberg P, Cappetta D, Solankhi NK, Fahsah I, Rokosh DG, Slaughter MS, Kajstura J, Anversa P. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): Initial results of a randomised phase 1 trial. Lancet 2011;378:1847-1857.
98. Simons M, Annex BH, Laham RJ, Kleiman N, Henry T, Dauerman H, Udelson JE, Gervino EV, Pike M, Whitehouse MJ, Moon T, Chronos NA. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: Double-blind, randomized, controlled clinical trial. Circulation 2002;105:788-793.
99. Henry TD, Annex BH, McKendall GR, Azrin MA, Lopez JJ, Giordano FJ, Shah PK, Willerson JT, Benza RL, Berman DS, Gibson CM, Bajamonde A, Rundle AC, Fine J, McCluskey ER. The VIVA trial: Vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation 2003;107:1359-1365.
100. Kastrup J, Jørgensen E, Rück A, Tägil K, Glogar D, Ruzyllo W, Bøtker HE, Dudek D, Drvota V, Hesse B, Thuesen L, Blomberg P, Gyöngyösi M, Sylvén C. Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris A randomized doubleblind placebo-controlled study: The Euroinject One trial. J Am Coll Cardiol 2005;45:982-988.
101. Greenberg B, Butler J, Felker GM, Ponikowski P, Voors AA, Desai AS, Barnard D, Bouchard A, Jaski B, Lyon AR, Pogoda JM, Rudy JJ, Zsebo KM. Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): A randomised, multinational, double-blind, placebo-controlled, phase 2b trial. Lancet 2016;387:1178-1186.
102. Perin EC, Silva GV, Henry TD, Cabreira-Hansen MG, Moore WH, Coulter SA, Herlihy JP, Fernandes MR, Cheong BY, Flamm SD, Traverse JH, Zheng Y, Smith D, Shaw S, Westbrook L, Olson R, Patel D, Gahremanpour A, Canales J, Vaughn WK, Willerson JT. A randomized study of transendocardial injection of autologous bone marrow mononuclear cells and cell function analysis in ischemic heart failure (FOCUS-HF). Am Heart J 2011;161:1078-1087.
103. Perin EC, Willerson JT, Pepine CJ, Henry TD, Ellis SG, Zhao DX, Silva GV, Lai D, Thomas JD, Kronenberg MW, Martin AD, Anderson RD, Traverse JH, Penn MS, Anwaruddin S, Hatzopoulos AK, Gee AP, Taylor DA, Cogle CR, Smith D, Westbrook L, Chen J, Handberg E, Olson RE, Geither C, Bowman S, Francescon J, Baraniuk S, Piller LB, Simpson LM, Loghin C, Aguilar D, Richman S, Zierold C, Bettencourt J, Sayre SL, Vojvodic RW, Skarlatos SI, Gordon DJ, Ebert RF, Kwak M, Moyé LA, Simari RD. Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: The FOCUS-CCTRN trial. JAMA 2012;307:1717-1726.
104. Pokushalov E, Romanov A, Chernyavsky A, Larionov P, Terekhov I, Artyomenko S, Poveshenko O, Kliver E, Shirokova N, Karaskov A, Dib N. Efficiency of intramyocardial injections of autologous bone marrow mononuclear cells in patients with ischemic heart failure: A randomized study. J Cardiovasc Transl Res 2010;3:160-168.
105. Tse HF, Thambar S, Kwong YL, Rowlings P, Bellamy G, McCrohon J, Thomas P, Bastian B, Chan JJKF, Lo G, Ho CL, Chan WS, Kwong RY, Parker A, Hauser TH, Chan JJKF, Fong DYT, Lau CP. Prospective randomized trial of direct endomyocardial implantation of bone marrow cells for treatment of severe coronary artery diseases (PROTECT-CAD trial). Eur Heart J 2007;28:2998-3005.
106. van Ramshorst J, Bax JJ, Beeres SL, Dibbets-Schneider P, Roes SD, Stokkel MPM, de Roos A, Fibbe WE, Zwaginga JJ, Boersma E, Schalij MJ, Atsma DE. Intramyocardial bone marrow cell injection for chronic myocardial ischemia: A randomized controlled trial. JAMA 2009;301:1997-2004.
107. Losordo DW, Henry TD, Davidson C, Sup Lee J, Costa MA, Bass T, Mendelsohn F, Fortuin FD, Pepine CJ, Traverse JH, Amrani D, Ewenstein BM, Riedel N, Story K, Barker K, Povsic TJ, Harrington RA, Schatz RA. Intramyocardial, autologous CD34 cell therapy for refractory angina. Circ Res 2011;109:428-436.
108. Losordo DW, Schatz RA, White CJ, Udelson JE, Veereshwarayya V, Durgin M, Poh KK, Weinstein R, Kearney M, Chaudhry M, Burg A, Eaton L, Heyd L, Thorne T, Shturman L, Hoffmeister P, Story K, Zak V, Dowling D, Traverse JH, Olson RE, Flanagan J, Sodano D, Murayama T, Kawamoto A, Kusano KF, Wollins J, Welt F, Shah P, Soukas P, Asahara T, Henry TD. Intramyocardial transplantation of autologous CD34 stem cells for intractable angina: A phase I/IIa double-blind, randomized controlled trial. Circulation 2007;115:3165-3172.
109. Wang WE, Yang D, Li L, Wang WE, Peng Y, Chen C, Chen P, Xia X, Wang H, Jiang J, Liao Q, Li Y, Xie G, Huang H, Guo Y, Ye L, Duan DD, Chen X, Houser SR, Zeng C. Prolyl hydroxylase domain protein 2 silencing enhances the survival and paracrine function of transplanted adipose-derived stem cells in infarcted myocardium. Circ Res 2013;113:288-300.
110. Perin EC, Sanz-Ruiz R, Sanchez PL, Lasso J, Pérez-Cano R, Alonso-Farto JC, Pérez-David E, Fernandez-Santos ME, Serruys PW, Duckers HJ, Kastrup J, Chamuleau S, Zheng Y, Silva GV, Willerson JT, Fernandez-Avilés F. Adiposederived regenerative cells in patients with ischemic cardiomyopathy: The PRECISE Trial. Am Heart J 2014;168:88-95.e2.
111. Seth S, Narang R, Bhargava B, Ray R, Mohanty S, Gulati G, Kumar L, Reddy KS, Venugopal P. Percutaneous intracoronary cellular cardiomyoplasty for nonischemic cardiomyopathy: Clinical and histopathological results: The first-in-man ABCD (Autologous Bone Marrow Cells in Dilated Cardiomyopathy) Trial. J Am Coll Cardiol 2006;48:2350-2351.
112. Vrtovec B, Poglajen G, Sever M, Lezaic L, Domanovic D, Cernelc P, Haddad F, Torre-Amione G. Effects of intracoronary stem cell transplantation in patients with dilated cardiomyopathy. J Card Fail 2011;17:272-281.
113. Bocchi EA, Bacal F, Guimaraes G, Mendroni A, Mocelin A, Filho AE, Dores da Cruz F, Resende MC, Chamone D. Granulocyte-colony stimulating factor or granulocyte-colony stimulating factor associated to stem cell intracoronary infusion effects in non ischemic refractory heart failure. Int J Cardiol 2010;138:94-97.
114. Vrtovec B, Poglajen G, Lezaic L, Sever M, Domanovic D, Cernelc P, Socan A, Schrepfer S, Torre-Amione G, Haddad F, Wu JC. Effects of intracoronary CD34 stem cell transplantation in nonischemic dilated cardiomyopathy patients: 5-year follow-up. Circ Res 2013;112:165-173.
115. Mushtaq M, DiFede DL, Golpanian S, Khan A, Gomes SA, Mendizabal A, Heldman AW, Hare JM. Rationale and design of the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis in Dilated Cardiomyopathy (the POSEIDON-DCM study): A phase I/II, randomized pilot study of the comparative safety and efficacy of transendocardial injection of autologous mesenchymal stem cell vs. allogeneic mesenchymal stem cells in patients with non-ischemic dilated cardiomyopathy. J Cardiovasc Transl Res 2014;7:769-780.
116. Prochazka V, Gumulec J, Jaluvka F, Salounova D, Jonszta T, Czerny D, Krajca J, Urbanec R, Klement P, Martinek J, Klement GL. Cell therapy, a new standard in management of chronic critical limb ischemia and foot ulcer. Cell Transplant 2010;19:1413-1424.
117. Ozturk A, Kucukardali Y, Tangi F, Erikci A, Uzun G, Bashekim C, Sen H, Terekeci H, Narin Y, Ozyurt M, Ozkan S, Sayan O, Rodop O, Nalbant S, Sildiroglu O, Yalniz FF, Senkal IV, Sabuncu H, Oktenli C. Therapeutical potential of autologous peripheral blood mononuclear cell transplantation in patients with type 2 diabetic critical limb ischemia. J Diabetes Complications 2012;26:29-33.
118. Losordo DW, Kibbe MR, Mendelsohn F, Marston W, Driver VR, Sharafuddin M, Teodorescu V, Wiechmann BN, Thompson C, Kraiss L, Carman T, Dohad S, Huang P, Junge CE, Story K, Weistroffer T, Thorne TM, Millay M, Runyon JP, Schainfeld R. A randomized, controlled pilot study of autologous CD34 cell therapy for critical limb ischemia. Circ Cardiovasc Interv 2012;5:821-830.
119. Perin EC, Silva G, Gahremanpour A, Canales J, Zheng Y, Cabreira-Hansen MG, Mendelsohn F, Chronos N, Haley R, Willerson JT, Annex BH. A randomized, controlled study of autologous therapy with bone marrow-derived aldehyde dehydrogenase bright cells in patients with critical limb ischemia. Catheter Cardiovasc Interv 2011;78:1060-1067.
120. Rajagopalan S, Mohler E, Lederman RJ, Saucedo J, Mendelsohn FO, Olin J, Blebea J, Goldman C, Trachtenberg JD, Pressler M, Rasmussen H, Annex BH, Hirsch AT. Regional angiogenesis with vascular endothelial growth factor (VEGF) in peripheral arterial disease: Design of the RAVE trial. Am Heart J 2003;145:1114-1118.
121. Belch J, Hiatt WR, Baumgartner I, Driver IV, Nikol S, Norgren L, Van Belle E. Effect of fibroblast growth factor NV1FGF on amputation and death: A randomised placebo-controlled trial of gene therapy in critical limb ischaemia. Lancet 2011;377:1929-1937.
122. Powell RJ, Simons M, Mendelsohn FO, Daniel G, Henry TD, Koga M, Morishita R, Annex BH. Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia. Circulation 2008;118:58-65.
123. Creager MA, Olin JW, Belch JJF, Moneta GL, Henry TD, Rajagopalan S, Annex BH, Hiatt WR. Effect of hypoxia-inducible factor-1alpha gene therapy on walking performance in patients with intermittent claudication. Circulation 2011;124:1765-1773.
124. Grossman PM, Mendelsohn F, Henry TD, Hermiller JB, Litt M, Saucedo JF, Weiss RJ, Kandzari DE, Kleiman N, Anderson RD, Gottlieb D, Karlsberg R, Snell J, Rocha-Singh K. Results from a phase II multicenter, double-blind placebo-controlled study of Del-1 (VLTS-589) for intermittent claudication in subjects with peripheral arterial disease. Am Heart J 2007;153:874-880.
125. Misra V, Ritchie MM, Stone LL, Low WC, Janardhan V. Stem cell therapy in ischemic stroke: Role of IV and intra-arterial therapy. Neurology 2012;79:S207-S212.
126. Wu J, Okamura D, Li M, Suzuki K, Luo C, Ma L, He Y, Li Z, Benner C, Tamura I, Krause MN, Nery JR, Du T, Zhang Z, Hishida T, Takahashi Y, Aizawa E, Kim NY, Lajara J, Guillen P, Campistol JM, Esteban CR, Ross PJ, Saghatelian A, Ren B, Ecker JR, Izpisua Belmonte JC. An alternative pluripotent state confers interspecies chimaeric competency. Nature 2015;521:316-321.
127. Jansen Of Lorkeers SJ, Doevendans PA, Chamuleau SAJ. All preclinical trials should be registered in advance in an online registry. Eur J Clin Invest 2014;44:891-892.
128. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research. PLoS Biol 2010;8:e1000412.
129. Jones SP, Tang X-L, Guo Y, Steenbergen C, Lefer DJ, Kukreja RC, Kong M, Li Q, Bhushan S, Zhu X, Du J, Nong Y, Stowers HL, Kondo K, Hunt GN, Goodchild TT, Orr A, Chang CC, Ockaili R, Salloum FN, Bolli R. The NHLBIsponsored Consortium for preclinicAl assESsment of cARdioprotective therapies (CAESAR): A new paradigm for rigorous, accurate, and reproducible evaluation of putative infarct-sparing interventions in mice, rabbits, and pigs. Circ Res 2015;116:572-586.
130. Bianconi E, Piovesan A, Facchin F, Beraudi A, Casadei R, Frabetti F, Vitale L, Pelleri MC, Tassani S, Piva F, Perez-Amodio S, Strippoli P, Canaider S. An estimation of the number of cells in the human body. Ann Hum Biol 2013;40:301-4460.
131. Liu J, Laksman Z, Backx PH. The electrophysiological development of cardiomyocytes. Adv Drug Deliv Rev 2015;96:253-273.
132. Fallahiarezoudar E, Ahmadipourroudposht M, Idris A, Mohd Yusof N, Mohd N, Mohd Yusof N. A review of: Application of synthetic scaffold in tissue engineering heart valves. Mater Sci Eng C 2015;48:556-565.
133. Jana S, Lerman A. Bioprinting a cardiac valve. Biotechnol Adv 2015;33: 1503-1521.
134. Namiri M, Ashtiani MK, Mashinchian O, Hasani-Sadrabadi MM, Mahmoudi M, Aghdami N, Baharvand H. Engineering natural heart valves: Possibilities and challenges. J Tissue Eng Regen Med 2016;1:1-9.
135. Tudorache I, Horke A, Cebotari S, Sarikouch S, Boethig D, Breymann T, Beerbaum P, Bertram H, Westhoff-Bleck M, Theodoridis K, Bobylev D, Cheptanaru E, Ciubotaru A, Haverich A. Decellularized aortic homografts for aortic valve and aorta ascendens replacement. Eur J Cardio-Thoracic Surg 2016;50:89-97.
136. Neofytou E, O'brien CG, Couture LA, Wu JC, Brien CGO, Couture LA, Wu JC. Hurdles to clinical translation of human induced pluripotent stem cells. J Clin Invest 2015;125:2551-2557.
137. Mathur A, Ma Z, Loskill P, Jeeawoody S, Healy KE. In vitro cardiac tissue models: Current status and future prospects. Adv Drug Deliv Rev 2015;96:203-213.
138. Stillitano F, Turnbull IC, Karakikes I, Nonnenmacher M, Backeris P, Hulot JS, Kranias EG, Hajjar RJ, Costa KD. Genomic correction of familial cardiomyopathy in human engineered cardiac tissues. Eur Heart J 2016;103:472-480.
139. Terzic A, Behfar A, Filippatos G. Clinical development plan for regenerative therapy in heart failure. Eur J Heart Fail 2016;18:142-144.
140. Bayon Y, Vertès AA, Ronfard V, Egloff M, Snykers S, Salinas GF, Thomas R, Girling A, Lilford R, Clermont G, Kemp P. Translating cell-based regenerative medicines from research to successful products: Challenges and solutions. Tissue Eng Part B Rev 2014;20:246-256.
141. Eaker S, Armant M, Brandwein H, Burger S, Campbell A, Carpenito C, Clarke D, Fong T, Karnieli O, Niss K, Van't Hof W, Wagey R. Concise review: Guidance in developing commercializable autologous/patient-specific cell therapy manufacturing. Stem Cells Transl Med 2013;2:871-883.
142. Abbasalizadeh S, Baharvand H. Technological progress and challenges towards cGMP manufacturing of human pluripotent stem cells based therapeutic products for allogeneic and autologous cell therapies. Biotechnol Adv 2013;31:1600-1623.
143. Freyman T, Polin G, Osman H, Crary J, Lu M, Cheng L, Palasis M, Wilensky RL. A quantitative, randomized study evaluating three methods of mesenchymal stem cell delivery following myocardial infarction. Eur Heart J 2006;27:1114-1122.
144. Hou D, Youssef EAS, Brinton TJ, Zhang P, Rogers P, Price ET, Yeung AC, Johnstone BH, Yock PG, March KL. Radiolabeled cell distribution after intramyocardial, intracoronary, and interstitial retrograde coronary venous delivery: Implications for current clinical trials. Circulation 2005;112:I150-I156.
145. van der Spoel TIG, Vrijsen KR, Koudstaal S, Sluijter JPG, Nijsen JFW, de Jong HW, Hoefer IE, Cramer M-JM, Doevendans PA, van Belle E, Chamuleau SAJ. Transendocardial cell injection is not superior to intracoronary infusion in a porcine model of ischaemic cardiomyopathy: A study on delivery efficiency. J Cell Mol Med 2012;16:2768-2776.
146. van den Akker F, Feyen DAM, van den Hoogen P, van Laake LW, van Eeuwijk ECM, Hoefer I, Pasterkamp G, Chamuleau SAJ, Grundeman PF, Doevendans PA, Sluijter JPG. Intramyocardial stem cell injection: Go(ne) with the flow. Eur Heart J 2017;38:184-186.
147. Gyöngyösi M, Wojakowski W, Lemarchand P, Lunde K, Tendera M, Bartunek J, Marban E, Assmus B, Henry TD, Traverse JH, Moyé LA, Sürder D, Corti R, Huikuri H, Miettinen J, Wöhrle J, Obradovic S, Roncalli J, Malliaras K, Pokushalov E, Romanov A, Kastrup J, Bergmann MW, Atsma DE, Diederichsen A, Edes I, Benedek I, Benedek T, Pejkov H, Nyolczas N, Pavo N, Bergler-Klein J, Pavo IJ, Sylven C, Berti S, Navarese EP, Maurer G. Meta-analysis of cell-based CaRdiac stUdiEs (ACCRUE) in patients with acute myocardial infarction based on individual patient data. Circ Res 2015;116:1346-1360.
148. Feyen D, Gaetani R, Liu J, Noort W, Martens A, Den Ouden K, Doevendans PA, Sluijter JPG. Increasing short-term cardiomyocyte progenitor cell (CMPC) survival by necrostatin-1 did not further preserve cardiac function. Cardiovasc Res 2013;99:83-91.
149. Vrtovec B, Poglajen G, Lezaic L, Sever M, Socan A, Domanovic D, Cernelc P, Torre-Amione G, Haddad F, Wu JC. Comparison of transendocardial and intracoronary CD34 cell transplantation in patients with nonischemic dilated cardiomyopathy. Circulation 2013;128:S42-S49.
150. Costa KD. Decellularized scaffold hydrogel materials for MI treatment. J Am Coll Cardiol 2016;67:1087-1090.
151. Stanley K. Design of randomized controlled trials. Circulation 2007;115: 1164-1169.
152. Banovic M, Loncar Z, Behfar A, Vanderheyden M, Beleslin B, Zeiher A, Metra M, Terzic A, Bartunek J. Endpoints in stem cell trials in ischemic heart failure. Stem Cell Res Ther 2015;6:1-9.
153. Hare JM, Bolli R, Cooke JP, Gordon DJ, Henry TD, Perin EC, March KL, Murphy MP, Pepine CJ, Simari RD, Skarlatos SI, Traverse JH, Willerson JT, Szady AD, Taylor DA, Vojvodic RW, Yang PC, Moyé LA; Cardiovascular Cell Therapy Research Network. Phase II clinical research design in cardiology: Learning the right lessons too well: Observations and recommendations from the Cardiovascular Cell Therapy Research Network (CCTRN). Circulation 2013;127:1630-1635.
154. De Groot V, Beckerman H, Lankhorst GJ, Bouter LM. How to measure comorbidity: A critical review of available methods. J Clin Epidemiol 2003;56:221-229.
155. Turner LGL, Knoepfler PPS, Chirba M, Garfield S, Connolly R, O'brien T, Flaherty G, Knoepfler PPS, Lau D, Ogbogu U, Taylor B, Stafinski T, Menon D, Caulfield T, McAllister TN, Audley D, L'heureux N, Ogbogu U, Rachul C, Caulfield T, Regenberg AC, Hutchinson LA, Schanker B, Mathews DJ, Turner LGL, Turner LGL. Selling stem cells in the USA: Assessing the direct-toconsumer industry. Cell Stem Cell 2016;1:233-272.